Reacción a "Phase 3 trial shows efficacy of new antibiotic against gonorrhoea"

This study demonstrates, with solid data, that zoliflodacin—a new oral antibiotic—may become an effective alternative in the face of growing resistance in the treatment of gonorrhoea. The WHO and the CDC [Centres for Disease Control and Prevention, in the US] consider resistant gonorrhoea a priority threat due to levels of resistance to ceftriaxone—our first-line drug—of up to 30% in Southeast Asia.

In our setting, where ceftriaxone remains effective, I see zoliflodacin as a second-line option, especially in situations where the usual treatment is not effective.